LEVERAGE LONG - ASTRAZENECA | Real-time Euronext Paris 09:14:42 2024-05-21 am EDT | ||
| 106 EUR | +4.14% |
|
| Current month | +1.72% | ||
| 1 month | +53.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 106 | +4.14% |
| 24-05-20 | 101.8 | +0.12% |
| 24-05-17 | 101.7 | -2.65% |
| 24-05-16 | 104.5 | -1.02% |
| 24-05-15 | 105.5 | -3.73% |
Real-time Euronext Paris
Last update May 21, 2024 at 09:14 am EDT
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| 11Z2S | |
| ISIN | DE000SD46UX4 |
| Date issued | 2021-04-01 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 58.74 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 266.6 € |
|---|---|
| Lowest since issue | 34.22 € |
| Spread | 0.67 € |
| Spread % | 0.63% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
168.1
USD
Spread / Average Target
+9.41%
- Stock Market
- Certificates
- 11Z2S Certificat